Metraipolis › archive › dc_6934a4c8cd07

Methodological and regulatory considerations for causal AI in drug development — Europe PMC PMID:41760772

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41760772
DOI
10.1038/s41746-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-10-06T17:57:28.567Z
SHA-256 of the archived text
b397b7a33ee66b7e8fc10dcad5862c3cb0cb4539b9178f933438a1f798780809
Stable URL of this page
https://metraipolis.com/documento/dc_6934a4c8cd07

How to cite

Methodological and regulatory considerations for causal AI in drug development — Europe PMC PMID:41760772 — Europe PMC (en), https://europepmc.org/article/MED/41760772 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6934a4c8cd07 (Metraipolis archive dc_6934a4c8cd07, sha256 b397b7a33ee66b7e8fc10dcad5862c3cb0cb4539b9178f933438a1f798780809)
BibTeX
@misc{dc6934a4c8cd07,
  title = {Methodological and regulatory considerations for causal AI in drug development — Europe PMC PMID:41760772},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41760772},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6934a4c8cd07; sha256 b397b7a33ee66b7e8fc10dcad5862c3cb0cb4539b9178f933438a1f798780809},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41760772. Agents can read the archived copy with the MCP tool read_document.